MD Anderson Research Highlights for January 26, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic,...
MD Anderson researchers elected as AAAS Fellows
In honor of their notable contributions to the field of cancer research, Juan Fueyo, M.D., and Victor Prieto, M.D., Ph.D., from The...
MD Anderson and Yingli Pharma initiate strategic...
The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several...
Nano-sized vesicles with ACE2 receptor could prevent, treat...
Scientists at The University of Texas MD Anderson Cancer Center and Northwestern Medicine have identified natural extracellular...
MD Anderson and Eisbach Bio announce strategic...
The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly...
MD Anderson Research Highlights for January 12, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic,...
Blood test helps predict who may benefit from lung cancer...
A blood test, combined with a risk model based on an individual’s history, more accurately determines who is likely to benefit from...
Relatlimab plus nivolumab improves progression-free...
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the...